Literature DB >> 15085972

Transpupillary thermotherapy in the treatment of choroidal metastasis from breast carcinoma.

Raul N G Vianna1, Rafael Pena, Acácio Muralha, Lília Muralha, Eduardo Muranaka.   

Abstract

BACKGROUND: Most patients who develop metastatic carcinoma to the choroid are managed by local radiation or chemotherapy. Since transpupillary thermotherapy (TTT) is currently gaining attention as an optional treatment for choroidal melanomas and hemangiomas, we sought to determine whether TTT is suitable for treatment of solitary choroidal metastasis at the posterior pole.
METHOD: We report on a patient with decreased vision due to a serous macular detachment in a eye with a solitary choroidal metastasis from breast carcinoma, who was managed by TTT.
RESULTS: After two months of follow up, total re-absorption of the serous macular detachment was achieved and the patient recovered full visual acuity in the treated eye. The choroidal mass became atrophic and hyperpigmentation of the retinal pigment epithelium and retinal folds in the macular region were observed. After six months of TTT, the ocular picture remained unchanged.
CONCLUSION: TTT can be considered an acceptable therapeutic option for solitary choroidal metastasis associated with serous retinal detachment.

Entities:  

Mesh:

Year:  2004        PMID: 15085972     DOI: 10.1023/b:inte.0000018525.92811.e4

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  9 in total

1.  Solitary choroidal metastasis managed by transpupillary thermotherapy.

Authors:  H Kiratli; S Bilgiç
Journal:  Eye (Lond)       Date:  2000-10       Impact factor: 3.775

2.  Histopathological findings in human choroidal melanomas after transpupillary thermotherapy.

Authors:  J G Journée-de Korver; J A Oosterhuis; D de Wolff-Rouendaal; H Kemme
Journal:  Br J Ophthalmol       Date:  1997-03       Impact factor: 4.638

Review 3.  Thermotherapy in the management of choroidal melanoma.

Authors:  J G Journée-de Korver; J E E Keunen
Journal:  Prog Retin Eye Res       Date:  2002-05       Impact factor: 21.198

4.  Transpupillary thermotherapy: results in 50 patients with choroidal melanoma.

Authors:  J A Oosterhuis; H G Journée-de Korver; J E Keunen
Journal:  Arch Ophthalmol       Date:  1998-02

5.  Transpupillary thermotherapy for circumscribed choroidal hemangiomas.

Authors:  J García-Arumí; L S Ramsay; B C Guraya
Journal:  Ophthalmology       Date:  2000-02       Impact factor: 12.079

6.  Survey of 520 eyes with uveal metastases.

Authors:  C L Shields; J A Shields; N E Gross; G P Schwartz; S E Lally
Journal:  Ophthalmology       Date:  1997-08       Impact factor: 12.079

7.  Indocyanine green augmented transpupillary thermotherapy in the management of choroidal metastasis from breast carcinoma.

Authors:  P Puri; M Gupta; P A Rundle; I G Rennie
Journal:  Eye (Lond)       Date:  2001-08       Impact factor: 3.775

8.  Thermal and optical properties of living tissue: application to laser-induced hyperthermia.

Authors:  L O Svaasand; T Boerslid; M Oeveraasen
Journal:  Lasers Surg Med       Date:  1985       Impact factor: 4.025

9.  Transpupillary thermotherapy in choroidal melanomas.

Authors:  J A Oosterhuis; H G Journée-de Korver; H M Kakebeeke-Kemme; J C Bleeker
Journal:  Arch Ophthalmol       Date:  1995-03
  9 in total
  3 in total

1.  Transpupillary thermotherapy in the treatment of circumscribed choroidal hemangiomas.

Authors:  Raul N G Vianna; Luiza Fernandes; Acácio Muralha; Aderbal Alves Júnior; Lilia Muralha; Eduardo Muranaka
Journal:  Int Ophthalmol       Date:  2004-03       Impact factor: 2.031

2.  Complete regression of a choroidal metastasis secondary to breast cancer with stereotactic radiation: case report and review of literature.

Authors:  Yarah M Haidar; Bobby S Korn; Mary Ann Rose
Journal:  J Radiosurg SBRT       Date:  2013

Review 3.  Choroidal metastases: origin, features, and therapy.

Authors:  Sruthi Arepalli; Swathi Kaliki; Carol L Shields
Journal:  Indian J Ophthalmol       Date:  2015-02       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.